title: New perspectives on glutamate receptor antagonists as antidepressants.
abstract: Classical antidepressants elevate the monoamine levels in the brain by preventing re-uptake of monoamines after release. Treatment of depression with monoamine re-uptake inhibitors is associated with low clinical efficacy and remission rate due to the delayed onset of therapeutic responses. Therefore, the development of alternative antidepressants is essential for successful treatment of this disease. Recently, glutamate receptor antagonists including ketamine and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) have received wide attention as fast-acting therapeutic alternatives for treatment of depression.
authors.affiliation: Department of Biological Sciences, Konkuk University, Seoul, 143-701, Korea. cchung@konkuk.ac.kr
authors.forename: Chihye
authors.initials: C
authors.lastname: Chung
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism; D055808:Drug Discovery; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015394:Molecular Structure; D017470:Receptors, Glutamate / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D018691:Excitatory Amino Acid Antagonists; D017470:Receptors, Glutamate